 |
| Boston Scientific is launching a new clinical trial to develop its Vercise DBS system.--Courtesy of Boston Scientific |
Boston Scientific ($BSX) is ramping up neuromodulation efforts with a new clinical trial of its implantable deep brain stimulation device for patients with Parkinson's disease.
The multicenter, prospective study will examine the company's Vercise Deep Brain Stimulation (DBS) system in up to 300 Parkinson's patients at international hospitals. The device runs leads into the brain and delivers electrical stimulation to improve motor function. Vercise is also paired with 3-D imaging technology that allows physicians to target certain areas of the brain and customize treatment for each patient.
"Boston Scientific is dedicated to supporting clinical research to bring forth innovative technologies that can help improve the quality of life for patients," Maulik Nanavaty, president of the company's neuromodulation unit, said in a statement. "This registry will enable us to provide physicians with a comprehensive, long term view of real world experience and results with the Vercise DBS System for the many patients affected by Parkinson's disease."
The trial builds upon previous data from a 6-month study which showed that the company's DBS device delivered a 60% average improvement in motor function in 40 patients with 100% implant success. In June 2013, Boston Scientific launched a large-scale trial of its DBS system with its eye on FDA approval; the technology has already won a CE mark and Australian regulatory approval, but has yet to be approved for use or sale in the U.S., the company said in a statement.
Positive study results could help Boston Scientific stay a step ahead of its competition and strengthen its hold on a growing market. The company's neuromodulation revenue jumped 32% in Q4 2013 to $138 million and is expected to grow to $648 million by 2018--second only to Medtronic's ($MDT) nerve-stimulating unit.
In addition to its Vercise device, Boston Scientific is also developing its next-generation Precision Spectra spinal cord stimulation implant. The device won the FDA's OK to treat chronic back pain in April 2013.
- read the release
Special Report: So far, just 4 companies have a shot at winning the neuromodulation race - Boston Scientific - Working hard to reach Medtronic
Related Articles:
Boston Scientific partners up to push Parkinson's tech in Europe
Boston Scientific targets FDA with brain-stim trial
Boston Scientific wins CE mark for deep-brain visualizer